Citations

Showing 10 of 108104 citations.

Increasing nonalcoholic steatohepatitis overlap in liver transplant recipients: Additive risk for de novo malignancy
Nasser‐Ghodsi, Navine , Mara, Kristin C. , Watt, Kymberly D. , Mara, Kristin, Watt, K D , Mara, Kristin C , Allen, Alina M.

Mayo Clinic

Clinical Transplantation | May 20, 2022 | Volume: 36 | Issue: 8 | Pages: No page available

10.1111/ctr.14714 | PMID 35594161 Get It

AbstractBackground and aimsNonalcoholic steatohepatitis (NASH) is associated with metabolic conditions that increase the risk of de novo malignancy following transplant. Patients often have more than one underlying liver disease, which could change the risk of de novo malignancy. This study assessed the incidence of NASH overlap and its effect on de novo malignancy in liver transplant recipients.MethodsData was analyzed from the United Network for Organ Sharing database for all liver transplant recipients from 1997 to 2017 for NASH alone or in combination with another liver disease.ResultsThere is an increasing prevalence of NASH overlap. Of the 98,679 patients included in the analysis, 1238 had a de novo malignancy identified (7.4% by 5 years post‐transplant). The cumulative incidence of de novo malignancy increases in primary sclerosing cholangitis (PSC)/NASH overlap after 5 years and was increased in alcohol‐related liver disease (ALD)/NASH through 10 years compared to ether disease alone. NASH overlaps with “other” diseases experience a cumulative incidence similar to NASH and not the “other” disease. An increased risk of de novo solid organ malignancy was associated with older age, male gender, previous malignancy, and multiorgan transplant.ConclusionThe prevalence of liver transplant recipients with NASH overlap is increasing. These patients may experience different long‐term outcomes than patients with either diagnosis alone. De novo malignancy risk can be influenced by multiple factors and metabolic comorbidities. Further study of patients with overlap diagnoses is important moving forward to guide individualized care and cancer screening programs.
New Approaches to the Diagnosis of Rejection and Prediction of Tolerance in Liver Transplantation
Taner, Timuçin , Bruner, Julia , Emamaullee, Juliet , Bonaccorsi‐Riani, Eliano , Zarrinpar, Ali

Mayo Clinic

Transplantation | May 20, 2022 | Volume: 106 | Issue: 10 | Pages: 1952-1962

10.1097/tp.0000000000004160 | PMID 35594482 Get It

Immunosuppression after liver transplantation is essential for preventing allograft rejection. However, long-term drug toxicity and associated complications necessitate investigation of immunosuppression minimization and withdrawal protocols. Development of such protocols is hindered by reliance on current paradigms for monitoring allograft function and rejection status. The current standard of care for diagnosis of rejection is histopathologic assessment and grading of liver biopsies in accordance with the Banff Rejection Activity Index. However, this method is limited by cost, sampling variability, and interobserver variation. Moreover, the invasive nature of biopsy increases the risk of patient complications. Incorporating noninvasive techniques may supplement existing methods through improved understanding of rejection causes, hepatic spatial architecture, and the role of idiopathic fibroinflammatory regions. These techniques may also aid in quantification and help integrate emerging -omics analyses with current assessments. Alternatively, emerging noninvasive methods show potential to detect and distinguish between different types of rejection while minimizing risk of adverse advents. Although biomarkers have yet to replace biopsy, preliminary studies suggest that several classes of analytes may be used to detect rejection with greater sensitivity and in earlier stages than traditional methods, possibly when coupled with artificial intelligence. Here, we provide an overview of the latest efforts in optimizing the diagnosis of rejection in liver transplantation.
Who's on first … Na+, HCO3− or CO32−?
Romero, Michael F. , Romero, Michael F

Mayo Clinic

The Journal of Physiology | May 20, 2022 | Volume: 600 | Issue: 13 | Pages: 3005-3006

10.1113/jp282945 | PMID 35593728 Get It

Glutamate Efflux across the Blood–Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System
Gruenbaum, Benjamin F. , Frenkel, Amit , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Frenkel, Amit , Boyko, Matthew , Zlotnik, Alexander Anatolievich , Fleidervish, Ilya A.

Mayo Clinic

Metabolites | May 20, 2022 | Volume: 12 | Issue: 5 | Pages: 459

10.3390/metabo12050459 | PMID 35629963 Get It

Depression is a significant cause of disability and affects millions worldwide; however, antidepressant therapies often fail or are inadequate. Current medications for treating major depressive disorder can take weeks or months to reach efficacy, have troubling side effects, and are limited in their long-term capabilities. Recent studies have identified a new set of glutamate-based approaches, such as blood glutamate scavengers, which have the potential to provide alternatives to traditional antidepressants. In this review, we hypothesize as to the involvement of the glutamate system in the development of depression. We identify the mechanisms underlying glutamate dysregulation, offering new perspectives on the therapeutic modalities of depression with a focus on its relationship to blood–brain barrier (BBB) permeability. Ultimately, we conclude that in diseases with impaired BBB permeability, such as depression following stroke or traumatic brain injury, or in neurogenerative diseases, the glutamate system should be considered as a pathway to treatment. We propose that drugs such as blood glutamate scavengers should be further studied for treatment of these conditions.
A Comprehensive Review of PCSK9 Inhibitors
Coppinger, Caroline, Azemawah, Veronica, Hashemzadeh, Mehrnoosh , Hashemzadeh, Mehrnoosh , Movahed, Mohammad Reza , Peyton, Lee , Gregory, James

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | May 20, 2022 | Volume: 27 | Issue: No issue available | Pages: No page available

10.1177/10742484221100107 | PMID 35593194 Get It

Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations. However, patients who are statin intolerant or those who do not achieve their treatment goals while on high-intensity statin therapy, such as those with familial hypercholesterolemia, remain at risk. With the discovery of PCSK9 inhibitors, the ability to provide more aggressive treatment for patients with homozygous and heterozygous familial hypercholesterolemia has increased. Ezetimibe reduces LDL-C by 15%-20% when combined with statin. 2 , 3 Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been found to achieve profound reductions in LDL-C (54%-74%) when added to statins. They have shown dramatic effects at lowering major adverse cardiovascular events (MACE) in high-risk patients 4 with LDL-C levels ≥70 mg/dL and can be used in populations that are statin intolerant or not at goal levels with maximally tolerated statin therapy. PCSK9 inhibitors also produce minimal side effects. Myopathy, a common side effect for patients on statins, has been rare in patients on PCSK9 inhibitors. Randomized trials have shown that reduction in LDL-C has translated to clinical benefits even in patients who have not achieved their LDL-C target.
Sodium‐glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation
Lemke, Adley , Brokmeier, Hannah M., Leung, Sarah B., Mara, Kristin C. , Wadei, Hani M. , Hill, Jennifer M. , Stegall, Mark D. , Kudva, Yogish C. , Shah, Pankaj, Kukla, Aleksandra , Mour, Girish K., Stegall, Mark D , Kudva, Yogish C. , Kukla, Aleksandra , Mara, Kristin C , Lemke, Adley I , Wadei, Hani M , Mour, Girish , Shah, Pankaj

Mayo Clinic

Clinical Transplantation | May 20, 2022 | Volume: 36 | Issue: 8 | Pages: No page available

10.1111/ctr.14718 | PMID 35593882 Get It

Abstract Introduction Diabetes mellitus in kidney transplant recipients is a risk factor for cardiovascular events and premature death. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are increasingly used in nontransplant populations to improve diabetes control and cardiovascular and renal benefits. Limited literature exists regarding the safety and efficacy of these agents in renal transplant recipients. Methods We retrospectively reviewed all kidney transplant recipients within our health system who were prescribed a SGLT2i after transplantation for diabetes. The safety, tolerability, and effectiveness of SGLT2i were analyzed. Results Thirty‐nine kidney transplant recipients were initiated on SGLT2i therapy, twenty‐seven of which remained on therapy for at least 1 year. Ten (25%) patients experienced an adverse event while on a SGLT2i, with urinary tract infections (UTI) being the most common. Seventeen patients (43%) discontinued the SGLT2i at the time of chart review, most commonly due to cost and kidney function decline. The median [IQR] hemoglobin A1c (HbA1c) at SGLT2i initiation of 8.4% [7.8–9.2] decreased to 7.5% [6.8–8.0%] after 3 months and 7.5% [6.5–7.9] after 12 months. No meaningful change in kidney function or tacrolimus exposure was observed. Conclusion SGLT2i may be a safe and effective treatment for diabetes in kidney transplant recipients. Cost is a barrier to SGLT2i therapy, and UTIs were the most frequently encountered adverse events in this cohort. More studies are needed to understand the safety profile and determine the effect of SGLT2i on diabetes‐related comorbidities among kidney transplant recipients.
The impact of pre‐morbid headaches on headache features and long‐term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research
Leibovit‐Reiben, Zachary , Ishii, Ryotaro , Dodick, David W. , Digre, Kathleen B. , Leibovit-Reiben, Zachary , Dodick, David W , Dumkrieger, Gina , Cortez, Melissa , Brennan, K. C. , Schwedt, Todd J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 20, 2022 | Volume: 62 | Issue: 5 | Pages: 566-576

10.1111/head.14311 | PMID 35593782 Get It

Abstract Objective To investigate the impact of having headaches prior to traumatic brain injury (TBI) on headache features and long‐term patient health outcomes. Background and Methods This was an exploratory analysis of patients with TBI who were enrolled in the American Registry for Migraine Research (ARMR), a multicenter, prospective, longitudinal patient registry composed of patients with International Classification of Headache Disorders, 3rd edition (ICHD‐3)–defined headache diagnoses. The ARMR study enrolled 2,707 patients between February 1, 2016 and May 6, 2020, 565 of whom qualified for this analysis. Those with headaches prior to their TBI were compared to those without headaches prior to their TBI for ICHD‐3 diagnoses, headache frequency and intensity, headache‐related disability (Migraine Disability Assessment score), symptoms of anxiety (General Anxiety Disorder [GAD‐7]), depression (two items from Patient Health Questionnaire‐9), post‐traumatic stress disorder (PTSD), cutaneous allodynia (12‐item Allodynia Symptom Checklist [ASC‐12]), cognitive dysfunction (Migraine Attacks Subjective Cognitive Impairments Scale [Mig‐SCog]), pain interference (Patient‐Reported Outcomes Measurement Information System‐Pain Interference), and work productivity (Work Productivity and Activity Impairment). Results Among 565 participants with TBI, 350 had headaches prior to their TBI. Those with pre‐TBI headaches were less likely to receive a diagnosis of post‐traumatic headache (PTH; 14/350 [4.0%] vs. 21/215 [9.8%], p = 0.006), even though 25.7% reported new or worsening headaches within 7 days of their TBI. Those with pre‐TBI headaches had higher ASC‐12 scores (2.4 ± 3.5 vs. 1.8 ± 3.4, p = 0.030), Mig‐SCog scores (9.3 ± 4.7 vs. 8 ± 4.9, p = 0.004), and GAD‐7 scores (6.9 ± 5.1 vs. 6.2 ± 5.4, p = 0.039), and were more likely to have a migraine diagnosis (335/350 [95.7%] vs. 192/215 [89.3%], p = 0.003). Conclusions Those with headaches prior to TBI are less likely to receive a diagnosis of PTH. They have more severe symptoms of cutaneous allodynia, cognitive impairment, and generalized anxiety. This analysis suggests that pre‐TBI headaches might impact post‐TBI headache diagnoses and associated features.
Risk Factors of Futile Recanalization Following Endovascular Treatment in Patients With Large‐Vessel Occlusion: Systematic Review and Meta‐Analysis
Abbasi, Mehdi , Liu, Yang , Brinjikji, Waleed , Savastano, Luis , Shahid, Adnan H , Larco, Jorge L. Arturo, Madhani, Sarosh Irfan , Savastano, Luis E , Liu, Yang , Shahid, Adnan Hussain , Larco, Jorge Arturo

Mayo Clinic

Stroke: Vascular and Interventional Neurology | May 20, 2022 | Volume: 2 | Issue: 6 | Pages: No page available

10.1161/svin.121.000257 | PMID 41582963 Get It

Background Although successful recanalization (modified Thrombolysis in Cerebral Infarction score 2b–3) can be achieved in >80% of patients experiencing stroke attributable to large‐vessel occlusion, up to 50% of patients may develop poor clinical outcomes (modified Rankin scale score at 90 days of 3–6), termed as futile recanalization (FR). The meta‐analysis aims to determine various risk factors associated with FR. Methods In February 2021, a comprehensive literature search on risk factors associated with FR was performed with keywords, including “stroke,” “thrombectomy,” “treatment outcome,” and “risk factors.” Their correlations with FR were evaluated using the random effect size meta‐analysis model. Results Twenty studies with 3037 patients were included with an FR rate of 51.0%. Our meta‐analyses showed that age (mean difference [MD], 5.6; 95% CI, 4.7–6.6), National Institutes of Health Stroke Scale score (MD, 4.2; 95% CI, 3.2–5.1), Alberta Stroke Program Early Computed Tomography (CT) Score (MD, −0.5; 95% CI, 0.8–0.3), hypertension (odds ratio [OR], 1.5; 95% CI, 1.3–1.9), systolic blood pressure (MD, 6.9; 95% CI, 3.6–8.7), atrial fibrillation (OR, 1.5; 95% CI, 1.2–1.8), IV tPA (tissue‐type plasminogen activator) (OR, 0.7; 95% CI, 0.5–0.8), puncture to recanalization time (MD, 9.6; 95% CI, 5.3–13.8), and time of onset to recanalization (MD, 32.1; 95% CI, 6.5–47.7) were significantly associated with FR ( P <0.001). Conclusions Age, admission National Institutes of Health Stroke Scale score, Alberta Stroke Program Early CT Score, comorbidities, including hypertension, systolic blood pressure, atrial fibrillation, and use of IV tPA, as well as time frames, including onset to recanalization and onset to arrival, were significant influencing factors for FR after mechanical thrombectomy. Future research on the mechanism underlying FR is warranted.
Automated extraction of anorectal pressures from high‐resolution manometry reports
Gautam, Misha , Mishra, Rahul , Oblizajek, Nicholas R. , Blackett, John W. , Bharucha, Adil E. , Blackett, John W William, Bharucha, A E , Oblizajek, Nicholas R , Elwazir, Mohamed Y.

Mayo Clinic

Neurogastroenterology & Motility | May 20, 2022 | Volume: 34 | Issue: 11 | Pages: No page available

10.1111/nmo.14411 | PMID 35593217 Get It

AbstractBackgroundDuring high‐resolution anorectal manometry (HR_ARM), the raw data are converted into software‐derived summary variables (e.g., rectoanal gradient during evacuation) that capture only a snapshot of the data collected during HR_ARM and are less useful than newer indices, which are also derived from the raw data, for diagnosing defecatory disorders (DD). However, it is cumbersome and time‐consuming to extract raw data from the program and calculate such indices. This study aimed to devise a user‐friendly approach to extract anorectal pressures measured with HR_ARM.MethodsAnorectal pressures at rest, during anal squeeze, and evacuation were measured with HR_ARM in 180 women, among whom 60 each were healthy, had DD, or fecal incontinence. A reverse engineering approach extracted pressure values from color images in HR_ARM reports. The summary variables generated by the software and a reverse engineering approach were compared with Lin's concordance correlation coefficient (CCC), pairedt‐tests, and Bland–Altman's tests.ResultsAnorectal pressures summarized by the software and a reverse engineering method were highly concordant for anal resting (CCC [95% CI], 0.98 [0.97, 0.99]) and squeeze pressures (0.99 [0.99, 0.99) and the rectoanal gradient during evacuation with an empty (0.98 [0.97, 0.98]) and a filled balloon (0.99 [0.99, 0.99]). For most variables, the paired t and Bland–Altman comparisons were not significant.ConclusionsAnorectal pressures can be accurately determined from pressure topography images in HR_ARM reports. In future, this reverse engineering approach can be harnessed to compile large HR_ARM datasets across centers and to uncover newer, potentially more useful summary rectoanal pressure variables.
Implementing Principles of Neuroontogenesis and Neuroplasticity for Spinal Cord Injury Therapy
Исламов, Р. Р. , Islamov, Rustem , Lavrov, Igor

Mayo Clinic

Frontiers in Bioscience-Landmark | May 20, 2022 | Volume: 27 | Issue: 5 | Pages: No page available

10.31083/j.fbl2705163 | PMID 35638430 Get It